DelveInsight’s “Tardive Dyskinesia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tardive Dyskinesia market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Tardive Dyskinesia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Tardive Dyskinesia: An Overview
According to National Organization for Rare Disorders (NORD), Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor-blocking drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum. The reasons that some people who take these drugs may get tardive dyskinesia and others do not is unknown. Tardive dystonia is a more severe form of tardive dyskinesia in which slower twisting movements of the neck and trunk muscles are prominent.
Tardive Dyskinesia Market Key Facts
-
As per a study conducted by Cornett et al. (2017) titled “Medication-Induced Tardive Dyskinesia: A Review and Update,” the occurrence of TD is estimated to be 2–5% annually, and the condition occurs in 15–30% of those who receive long-term treatment with antipsychotic drugs [APDs].
-
According to Mental Health America (MIIA), TD is estimated to affect at least 500,000 people in the US. Those who have been treated for schizophrenia, schizoaffective disorder, and bipolar disorder are particularly at risk.
-
As per the article published by Robert et al. (2019) titled “Tardive Dyskinesia Facts and Figures,” TD affects an estimated 500,000 persons in the United States. About 60% to 70% of cases are mild, and about 3% are extremely severe.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Tardive Dyskinesia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Tardive Dyskinesia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Tardive Dyskinesia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Tardive Dyskinesia Epidemiology Segmented by –
-
Prevalent Population of Tardive Dyskinesia
-
Diagnosed Prevalent Population of Tardive Dyskinesia
-
Treatable Cases of Tardive Dyskinesia
Tardive Dyskinesia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tardive Dyskinesia market or expected to get launched during the study period. The analysis covers the Tardive Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Tardive Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Tardive Dyskinesia Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/tardive-dyskinesia-market
Tardive Dyskinesia Therapeutics Market
The pipeline of Tardive Dyskinesia (TD) is very narrow, reflecting a high medical unmet need for potential treatment options for the patients. The limited number of pipeline therapies creates opportunities for other pharma and biotech giants to enter the therapeutics market.
Some of the key companies in the Tardive Dyskinesia market include
-
SOM Biotech
-
Teva Pharmaceutical
-
Neurocrine Biosciences
-
Contera Pharma
-
Addex Therapeutics
-
Mitsubishi Tanabe Pharma
and others.
Tardive Dyskinesia Therapies covered in the report include:
-
OM3355
-
JM-010
-
SOM3366
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tardive Dyskinesia Competitive Intelligence Analysis
4. Tardive Dyskinesia Market Overview at a Glance
5. Tardive Dyskinesia Disease Background and Overview
6. Tardive Dyskinesia Patient Journey
7. Tardive Dyskinesia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Tardive Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Tardive Dyskinesia Unmet Needs
10. Key Endpoints of Tardive Dyskinesia Treatment
11. Tardive Dyskinesia Marketed Products
12. Tardive Dyskinesia Emerging Drugs and Latest Therapeutic Advances
13. Tardive Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Tardive Dyskinesia Market Outlook (In US, EU5, and Japan)
16. Tardive Dyskinesia Access and Reimbursement Overview
17. KOL Views on the Tardive Dyskinesia Market
18. Tardive Dyskinesia Market Drivers
19. Tardive Dyskinesia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market
Other Trending Healthcare Reports By DelveInsight
Tardive Dyskinesia Pipeline Insights
“Tardive dyskinesia – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ drugs in Tardive dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/